Drug Discovery World

AUGUST 9, 2022

Provider to the life sciences industry BioIVT has acquired enzymes manufacturer Cypex in a bid to enhance its product portfolio. . Based in Dundee, Cypex manufactures recombinant xenobiotic metabolizing enzymes with its product portfolio covering a wide range of proteins involved in drug metabolism. . Richard Haigh.

In-Vitro 52

In-Vitro Protein Production Bacteria 52

XTalks

JANUARY 6, 2021

One nanobody in particular, called NIH-CoVnb-112, was shown to be able to prevent COVID-19 infection from the novel coronavirus by targeting both the spike protein on SARS-CoV-2, as well as the angiotensin converting enzyme 2 (ACE2) receptor that it binds to on human cells. The study was led by neuroscientists Thomas J. “TJ”

Antibody 105

Antibody Protein Bacteria In-Vitro 105

Drug Discovery World

OCTOBER 13, 2022

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery.

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52